Amphetamine
Centrally Acting Sympathomimetics
Sold as MYDAYIS · DYANAVEL XR
- Drug class
- Centrally Acting Sympathomimetics
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 30
- FDA reports (12 mo)
- 2,827
Overview
Plain-language summary, compiled from the cited regulatory records
Amphetamine is a medication classified as a centrally acting sympathomimetic [1]. It is approved for the treatment of narcolepsy and Attention Deficit Disorder with Hyperactivity (ADDH) [1]. For ADDH, amphetamine is intended as part of a comprehensive treatment plan that includes other interventions, such as psychological, educational, and social measures [1]. It is used to help manage behavioral symptoms in children characterized by distractibility, a short attention span, hyperactivity, and emotional lability [1].
Amphetamine is available under various brand names, including MYDAYIS [1]. In the past 12 months, there have been 2,827 adverse event reports associated with this active ingredient [2]. The most frequently reported adverse events include reports of the drug being ineffective, drug abuse, fatigue, toxicity, and nausea [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 25 | April 30, 2026 |
| CA Canada | Health Canada | 5 | May 22, 2026 |
USUnited States· FDA
25 products
Uses
INDICATIONS AND USAGE
Amphetamine sulfate tablets are indicated for:
Narcolepsy Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.
The diagnosis of the syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or not be warranted.
, repeated diets, group programs, and other drugs. The limited usefulness of amphetamines ( see CLINICAL PHARMACOLOGY ) should be weighed against possible risks inherent in use of the drug, such as those described below.
CACanada· Health Canada
5 products
5 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].
Brands in Canada (1)
Drug interactions
Known interactions involving Amphetamine. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 00242264-40d8-42… · revised May 24, 2023 [PDF]
- [2]Health Canada (DPD) · 02559781 · revised October 7, 2025
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.